The Company is directing all of its efforts and resources to Contrave(R) and Empatic(TM), its obesity product candidates. It anticipates announcing the results from the first Phase 3 clinical trial for Contrave in January.
About Orexigen Therapeutics
Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company's lead combination product candidates are Contrave, which is in Phase 3 clinical trials, and Empatic, which is in the later stages of Phase 2 clinical development. Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss. Further information about the company can be found at http://www.orexigen.com.
Orexigen cautions you that statements included in this press release that
are not a description of historical facts are forward-looking statements.
Words such as "believes," "anticipates," "plans," "expects," "indicates,"
"will," "intends," "potential," "suggests," "assuming," "designed" and similar
expressions are intended to identify forward-looking statements. These
statements are based on the Company's current beliefs and expectations. These
forward-looking statements include statements regarding the objectives of the
Company's organizational changes, the enrollment, timing, execution,
completion and announcement of results of clinical trials of Contrave and the
potential to obtain regulatory approval for, and effectively treat obesity
with its product candidates. The inclusion of forward-looking statements
should not be regarded as a representation by Orexigen that any of its plans
|SOURCE Orexigen Therapeutics, Inc.|
Copyright©2008 PR Newswire.
All rights reserved